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Low-dose human chorionic gonadotropin may
improve in vitro fertilization cycle outcomes in
patients with low luteinizing hormone levels after
gonadotropin-releasing hormone antagonist
administration
Anthony M. Propst, M.D.,a,b,c Micah J. Hill, D.O.,a Gordon Wright Bates, M.D.,b Michelle Palumbo, M.D.,b
Anne K. Van Horne, M.D.,b and Matthew G. Retzloff, M.D.b
a Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda, Maryland; b Division of Reproductive Endocrinology, Wilford Hall
Medical Center, San Antonio Uniformed Services Health Education Consortium, San Antonio, Texas; and c Uniformed
Services University of the Health Sciences, Bethesda, Maryland
Objective: To evaluate the effect of low levels of endogenous luteinizing hormone (LH) and low-dose human
chorionic gonadotropin (hCG) supplementation on in vitro fertilization (IVF) cycle outcomes in a gonadotropin-
releasing hormone (GnRH) antagonist protocol.
Design: Retrospective study.
Setting: Military medical center.
Patient(s): General in vitro fertilization/embryo transfer (IVF-ET) population.
Intervention(s): Addition of low-dose urinary hCG to IVF stimulations using a recombinant follicle-stimulating
hormone (FSH) and GnRH antagonist protocol.
Main Outcome Measure(s): Implantation and live-birth rates.
Result(s): As part of a larger cohort of 239 patients, 42 patients with LH levels%0.5 mIU/mL were evaluated. In
the larger cohort, there were no differences in implantation and pregnancy rates between the recombinant FSH only
(n¼ 113) and the recombinant FSH with low-dose hCG supplementation (n¼ 126) groups. In the FSH-only group,
patients with LH levels%0.5 mIU/mL had decreased implantation rates (19% vs. 42%) and live-birth rates (25%
vs. 54%) as compared with patients with LH levels >0.5 mIU/mL. Low LH patients in the recombinant FSH with
low-dose urinary hCG group had statistically significantly higher implantation rates (54% vs. 19%) and live-birth
rates (64% vs. 25%) as compared with patients with similar low LH levels in the recombinant FSH-only group.
Conclusion(s): Endogenous LH levels%0.5 mIU/mL after GnRH antagonist treatment are associated with statis-
tically significantly lower implantation and pregnancy rates in recombinant FSH-only cycles. The addition of low-
dose urinary hCG results in improved implantation and live-birth rates in patients with low LH levels. (Fertil Steril
2011;96:898–904. 2011 by American Society for Reproductive Medicine.)
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The use of gonadotropin-releasing hormone (GnRH) antagonists in
place of GnRH agonists has increased in in vitro fertilization (IVF)
stimulation protocols (1). Unlike GnRH agonists, which require pro-
longed administration for pituitary suppression, GnRH antagonists
allow for immediate suppression of pituitary gonadotropins (2). Ad-
ditional advantages of GnRH antagonists include reducing the
amount of exogenous gonadotropins required for IVF stimulation,
shortening the duration of stimulation, and avoiding a gonadotropin
flare (2). Rates of ovarian hyperstimulation syndrome are also de-
creased with GnRH antagonists (3). However, GnRH antagonists
cause a rapid and profound inhibition of endogenous luteinizing hor-
mone (LH) secretion (4–6), and this suppression occurs at a time
when the follicle is most sensitive to LH activity. As described in
the two-cell two-gonadotropin theory, normal follicular growth de-
pends on both FSH and LH, and it has been shown that low levels of
LH may negatively affect pregnancy and implantation rates (7). Al-
though the level of endogenous LH necessary for normal follicular
development is unknown, the conclusions from several studies sug-
gest that low levels of LH are associated with higher rates of early
pregnancy loss (7–9).
The effect of GnRH antagonist on LH and estradiol levels before
oocyte retrieval was studied in the ganirelix dose-finding study (10).
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It was shown that as the dose of ganirelix acetate increased, the se-
rum LH and estradiol concentrations decreased in a dose-dependent
manner (10). The number of good-quality embryos and the number
of embryos transferred in the four different dosage groups were sim-
ilar. However, the ongoing pregnancy rate was significantly lower in
the groups with low levels of LH and estradiol before oocyte re-
trieval (10).
Donor IVF cycles using GnRH antagonists that were supple-
mented with recombinant LH had significantly higher fertilization
and implantation rates (11). This suggests that GnRH antagonist
use with recombinant FSH alone may have a negative impact on fol-
licular growth and oocyte development. It is speculated that LH sup-
plementation is necessary for normal granulosa cell function in
GnRH antagonist cycles. These data indirectly suggest that low
LH levels might lead to decreased implantation and pregnancy rates.
Recent evidence also shows that supplementation of GnRH an-
tagonist cycles with human chorionic gonadotropin (hCG), a mimic
of endogenous LH, provides comparable pregnancy rates to cycles
using standard ovulation-induction protocols (12, 13). The
administration of hCG promotes follicular growth and oocyte
maturation, thereby decreasing the amount of FSH needed for
ovarian stimulation (12, 14, 15). We previously published a study
that showed that hCG supplementation results in lower medication
costs and similar pregnancy rates compared with FSH-only stimula-
tion for GnRH-antagonist IVF cycles (14). This retrospective study
determines the effects of profound LH suppression after GnRH an-
tagonist administration and determines whether low-dose hCG ad-
ministration was beneficial in this patient population.
MATERIALS AND METHODS
This retrospective analysis examined 239 IVF or ICSI cycles in patients aged
23 to 40 years during the period May 2002 to October 2005. Institutional re-
view board approval was obtained fromWilford Hall Medical Center. Inclu-
sion criteria included all women who underwent ovarian hyperstimulation
with recombinant FSH and ganirelix acetate (Merck) during this time period.
Ovarian stimulation with recombinant FSH alone occurred until May 2004.
After that all, patients were supplemented with low-dose hCG. An LH thresh-
old of%0.5 mIU/mL was chosen to further group patients for analysis. The
LH threshold of%0.5 mIU/mLwas chosen based on data demonstrating that
normogonadotropic patients with suppressed LH levels below this threshold
have a higher rate of abortion and lower chance of live birth (8). Due to the
retrospective nature of the study, a power analysis was not performed. The
specific time frame for analysis was chosen, and data were not analyzed
from other time periods so as not to introduce bias by choosing a time period
that showed results in a specific direction.
Pituitary down-regulation was achieved with combined oral contraceptives
(OCPs), which were started on day 5 of the cycle before ovarian stimulation.
In the group using FSH alone, recombinant FSH (Gonal F, EMDSerono; or
Follistim, Merck) was started at a dose of 150–600 IU per day (divided be-
tween a morning and evening dose) 5 days after discontinuation of combined
OCP. In the group that was supplemented with low-dose hCG, recombinant
FSH was started at a morning dose of 150 or 225 IU. Low-dose hCG (Pre-
gnyl; Merck) was started concomitantly with recombinant FSH and was
given in a daily evening dose of either 50 or 100 IU. The hCG dose was cho-
sen to replace the evening FSH dose, and patients were given 50 IU of hCG if
the FSH dose was less than 225 IU or 100 IU of hCG if the FSH dosewas 225
IU or more. Transvaginal ultrasound was performed after 4 days of stimula-
tion, and the dose of recombinant FSH and hCG was adjusted based on the
number and size of follicles and the estradiol level.
A daily morning dose of 250 mg of ganirelix acetate was started when lead
follicles were 13 to 14 mm in mean diameter. When there were at least two
follicles with a mean diameter ofR18 mm, with at least two additional fol-
licles sizedR10 mm, hCG was administered (5,000–10,000 IU). Oocyte re-
trieval was performed 36 hours later, and the embryos were transferred either
3 or 5 days after retrieval, depending on embryo number and quality. Luteal
phase support was maintained with 50 mg of progesterone intramuscular in-
jections daily beginning the evening after the oocyte retrieval and continuing
until 7 to 8 weeks’ estimated gestational age.
Serum LH and estradiol levels were measured before stimulation with
FSH, before the start of the GnRH antagonist, at several intervals after the
start of GnRH antagonist, and on the day of hCG administration for final oo-
cyte maturation. All serum tests were drawn in the morning before the morn-
ing doses of gonadotropins or ganirelix acetate were administered.
Luteinizing hormone and estradiol were measured by using an electrochemi-
luminescence immunoassay (Modular Analytics E170 module; Roche). The
detection limits for LH and estradiol were 0.10 mIU/mL and 5.0 pg/mL, re-
spectively. The intra-assay and interassay coefficients of variation were 1.2%
and 2.0%, respectively, at the lowest mean dose of LH. The intra-assay and
interassay coefficients of variation were 2.0% and 2.2%, respectively, at
a mean level of 3,715 pg/mol. The LH assay used shows no cross-
reactivity with FSH, thyroid-stimulating hormone (TSH), or hCG. Serum
hCG levels were not measured in this study, including in the patients in the
recombinant FSH þ hCG group.
Statistical Methods
All analyses were performed using SPSS 13 for Windows (SPSS, Inc.). Ex-
ploratory data analysis was initially performed to determine normality of the
data. The parametric continuous variables were analyzed by using Student’s
t-test, and the results are expressed as mean  standard deviation. The non-
parametric continuous or ordinal data were analyzed with theMann-Whitney
U test. Percentages or rates were compared by using either chi-square or
Fisher’s exact test, as indicated.
RESULTS
A total of 239 IVF-ICSI cycles were analyzed. Forty-two cycles
where patients had an LH level %0.5 mIU/mL were analyzed as
part of this larger cohort. Seven cycles were canceled before embryo
transfer, and two after oocyte retrieval had occurred. All of the can-
celed cycles were in the LH >0.5 IU/mL group. Patients were
grouped based on stimulation with or without low-dose hCG and
based on the lowest value of LH obtained at any point after the ini-
tiation of GnRH antagonist before the administration of hCG for fi-
nal oocyte maturation using a threshold of LH %0.5 mIU/mL or
greater. Any LH value%0.5 mIU/mL at any time after the start of
the GnRH antagonist qualified a patient to be placed in the low
LH group. There were 113 cycles in the FSH-only group and 126 cy-
cles in the FSH with low-dose hCG group. In the FSH-only group,
20 patients had LH levels %0.5 mIU/mL. In the FSH with low-
dose hCG group, 22 patients had LH levels%0.5 mIU/mL.
Estradiol and LH levels were measured at baseline and at each ul-
trasound visit through the administration of the hCG trigger shot
(Table 1). The baseline LH levels of the FSH-only and FSH with
low-dose hCG groups were similar (2.5  2.4 vs. 2.5  2.4 mIU/
mL, P¼.98). Patients in the low LH group who received FSH only
had lower baseline LH levels than did the patients in the normal
LH group who received FSH only (0.5  0.6 vs. 2.9  2.5 mIU/
mL, P<.01). Similarly, patients in the low LH group who received
low-dose hCG had lower baseline LH levels than did the patients
in the normal LH group who received low-dose hCG (1.1  2.2
vs. 2.5 2.4 mIU/mL, P<.01). The baseline LH levels were not dif-
ferent between the FSH-only and FSH with low-dose hCG groups
(0.33). The women in the FSH with low-dose hCG group were on
average 1 year older (P¼.04).
There were no differences in implantation, spontaneous abortion,
or live-birth rates between the groups receiving FSH only and FSH
with low-dose hCG (see Table 1). The FSH with low-dose hCG
group used less total FSH (1,868 vs. 2,899 IU, P<.01) and had
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higher peak estradiol levels (3,142 vs. 2,098 pg/mL, P<.01) than the
FSH-only group.
Table 2 shows the IVF cycle outcomes within the FSH-only
group, comparing patients with an LH level%0.5 mIU/mL to those
above this threshold. Patients with the low LH nadir had more oo-
cytes retrieved (21 vs. 13, P<.01) and more embryos (13.1 vs.
7.9, P<.01). Despite having more oocytes and embryos, the low
LH patients had statistically significantly lower implantation rates
(19% vs. 42%, P<.01), clinical pregnancy rates (30% vs. 59%,
P<.01), and live-birth rates (25% vs. 54%, P<.01) (Table 2).
Table 3 shows the IVF cycle outcomes in patients with LH
levels%0.5 mIU/mL, comparing those in the FSH-only group and
those in the FSH with low-dose hCG group. The patients receiving
FSH only had higher numbers of oocytes retrieved (21 vs. 13,
P<.01) and lower peak estradiol levels (1,972 vs. 3,373 pg/mL,
P<.01) as compared with patients receiving FSH with low-dose
hCG. Patients receiving low-dose hCG had higher implantation rates
(54% vs. 19%, P<.01), clinical pregnancy rates (68% vs. 30%,
P<.01), and higher live-birth rates (64% vs. 25%, P¼.01). Patients
receiving FSH stimulation only who had LH levels%0.5 mIU/mL
had statistically significantly lower implantation and live-birth rates
than all other patient groups (Fig. 1). Patients with LH levels%0.5
mIU/mL who received low-dose hCG supplementation had out-
comes similar to patients with normal LH levels (see Fig. 1).
DISCUSSION
Our data demonstrate a negative impact of suppressed LH levels be-
low a threshold of%0.5 mIU/mL before final oocyte maturation in
GnRH antagonist cycles. The negative impact of suppressed LH ac-
tivity was demonstrated by reduced implantation and live-birth
rates. We also show that the negative impact of suppressed LH levels
can be overcomewith the addition of LH activity in the form of low-
dose hCG. When patients were not supplemented with low-dose
hCG, there was a clear difference in outcomes between patients
with LH nadir levels %0.5 mIU/mL compared with those above
this level. Lower implantation rates and lower live-birth rates were
seen in the low LH group as compared with the group with higher
resting LH levels. Conversely, when hCG was given to patients
with low LH levels, their outcomes were improved and were similar
to patients without profound LH suppression. Low LH patients
given hCG had higher implantation rates and higher live-birth rates
when compared with low LH patients not supplemented with hCG.
Our data also demonstrated that patients with LH nadir levels%0.5
TABLE 1
Demographic and baseline characteristics and cycle











Age (y) 32.8  3.5 33.8  3.6 .04
Day–3 LH (mIU/mL) 2.5  2.4 2.5  2.4 .94
FSH administered
(IU)
2,898  1,010 1,868  573 < .01
HCG administered
(IU)
0 600  266
Peak estradiol
(pg/mL)a
2,098  1,183 3,142  1717 < .01
Oocytes retrieved 14.9  9.0 12.4  7.1 .02
Embryos 8.9  6.3 7.8  5.1 .15
Embryos transferred 2.2  0.5 2.2  0.5 .46







Live birth (%) 48 50 .59
Note: FSH ¼ follicle-stimulating hormone; hCG ¼ human chorionic go-
nadotropin; LH ¼ luteinizing hormone.
a Peak estradiol levels defined as estradiol on the day of 5,000 or 10,000
IU hCG.
Propst. Low LH levels in IVF. Fertil Steril 2011.
TABLE 2
Comparison of outcomes in the FSH-only group between
patients with an LH nadir of%0.5 mIU/mL versus those









Age (y) 33.8  3.1 32.6  3.5 .17
Peak estradiol 1,972  1,059 2,126  1,213 .06
Oocytes retrieved 21.4  10.0 13.4  6.3 < .01
Embryos 13.1  6.7 7.9  5.8 < .01
Embryos transferred 2.1  0.3 2.2  0.6 .57




Clinical pregnancy (%) 30 59 .03
Live birth (%) 25 54 < .01
Note: FSH ¼ follicle-stimulating hormone; LH ¼ luteinizing hormone.
Propst. Low LH levels in IVF. Fertil Steril 2011.
TABLE 3
Comparison of cycle outcomes between patients with
nadir LH levels%0.5mIU/mL in the FSHonly group and the








Age (y) 33.8  3.1 33.1  3.9 .50
Peak estradiol 1,972  1,059 3,373  1,504 < .01
Oocytes retrieved 21.4  10.0 13.5  6.3 < .01
Embryos 13.1  6.7 8.6  5.0 .02
Embryos transferred 2.1  0.3 2.1  0.4 .94




Clinical pregnancy (%) 30 68 < .01
Live birth (%) 25 64 .01
Note: FSH ¼ follicle-stimulating hormone; hCG ¼ human chorionic go-
nadotropin; LH ¼ luteinizing hormone.
Propst. Low LH levels in IVF. Fertil Steril 2011.
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mIU/mL had lower LH levels at baseline measurement than patients
with LH nadir levels >0.5 mIU/mL. This suggests the possibility
that patients who had a greater degree of LH suppression after
OCP treatment were at risk for more profound LH suppression after
GnRH antagonist treatment.
The concept of an LH threshold below which negative reproduc-
tive outcomes are seen has been well documented (8, 16–19). Our
data support the theory that there is an LH threshold below which
adverse effects are seen in human assisted reproduction. Studies
on patients with hypothalamic amenorrhea have shown the
addition of LH is necessary to achieve appropriate follicular and
endometrial development (20–25). However, it has also been
shown that many normogonadotropic patients can be stimulated
successfully with FSH alone in both GnRH antagonist and GnRH
agonist cycles (26–31). Presumably this is because many patients
have resting levels of LH that are adequate to initiate
steroidogenesis and promote oocyte maturity, despite GnRH
analogue down-regulation (32). There remains a cohort of patients
who develop profound LH suppression with GnRH analogue
treatment. A recent paper evaluating practices at consistently
high-performing IVF programs in the United States showed these
programs use a mixture of LH and FSH during ovarian stimulation
(33). Studies have shown that patients with low LH levels have
decreased estradiol levels, retarded follicular growth, decreased
pregnancy rates, and increased miscarriage rates (8, 16–18). The
LH threshold has been demonstrated to be between 0.5 and
1.2 mIU/mL in prior studies (8, 16, 18). We believe patients
below an LH threshold of 0.6 mIU benefit from the addition of
LH activity during IVF stimulation.
Both hCG and LH have the same alpha subunit, and both bind to
and activate postreceptor changes on the LH/hCG receptor. The beta
subunit of hCG has a different structure and glycosylation pattern
than LH, resulting in a sixfold increased affinity for the LH/hCG re-
ceptor and longer half-life (13). We have previously shown that
a low-dose hCG protocol also reduces IVF stimulation costs by an av-
erage of$600per cycle by reducing the amount ofFSHneeded to com-
plete stimulation (14). As low-dose hCG is a cost effective alternative
for adding LH activity and has demonstrable biologic activity at low
doses, we chose low-dose hCG as the source of LH activity in our
stimulation protocol. Other sources of LH activity include human
menopausal gonadotropin (hMG) and recombinant LH.
Our data show an increase in live-birth rates by increasing im-
plantation rates in patient with low LH levels who receive low-
dose hCG. It is possible that hCG either acts to increase the quality
of the oocytes themselves or that hCG is acting on the endometrium
to increase the likelihood of implantation. Luteinizing hormone acts
on the granulosa cells to generate increased substrate for estradiol
production. In our study and others, patients exposed to LH/hCG
have higher estradiol levels and generate more estradiol per follicle
(26, 28, 29, 34–41). Additionally, LH acts through postreceptor
paracrine factors such as amphiregulin and epiregulin. These
epidermal growth factor-like factors cause cumulous cell expansion
and trigger the oocyte to reenter the cell cycle and proceed through
meiosis I and have been shown to increase the maturation rate of
in vitro matured germinal vesicle–stage oocytes (42–44). Through
stimulation of the LH/hCG receptor, low-dose hCG may result in
a more reproductively competent oocyte.
The LH/hCG receptor has also been shown to be present in the
endometrium and to increase during the peri-implantation window.
Apoptosis of endometrial stromal cells can also be reduced by the
administration of hCG (45, 46). Additionally, hCG messenger
RNA (mRNA) is transcribed as early as the two-cell stage of the em-
bryo (47), and the hCG protein is already being secreted by the em-
bryo before implantation (48, 49). Thus, there appears to be an effect
of hCG on the regulation of the endometrium and on implantation
(50–53). The addition of LH activity in the form of hMG or
recombinant LH has been associated with an increase in
implantation rates (11, 38, 54, 55), although other studies have not
confirmed this finding (56, 57). In a recent randomized controlled
trial, Bosch et al. (58) showed that the addition of recombinant
LH to recombinant FSH in GnRH antagonist cycles results in im-
proved implantation rates in patients 36 to 39 years old but not in
younger patients. Our data show a similar implantation rate between
both treatment groups when LH levels were >0.5 mIU/mL. How-
ever, patients with low LH levels had higher implantation rates
when supplemented with low-dose hCG. This suggests that the ad-
dition of low-dose hCGmay improve the implantation process in pa-
tients with profound LH suppression in a GnRH antagonist cycle.
Our data are consistent with the literature in showing that patients
supplemented with LH/hCG have a greater amount of estradiol pro-
duction, a lower number of follicles that develop, and a decreased
amount of FSH needed to complete IVF stimulation. In several stud-
ies, Filicori et al. (59–61) have shown that addition of LH/hCG to
ovarian stimulation results in a regression of small ovarian
follicles without affecting the number of intermediate (10–14 mm)
or large (>14 mm) follicles. These data are confirmed in several
randomized controlled trials showing that the addition of either
FIGURE 1
Comparison of implantation and live-birth rates. Group
comparisons made between patients receiving follicle-stimulating
hormone (FSH) only with luteinizing hormone (LH)%0.5 mIU/mL
(blue bar), patients receiving FSH only with LH nadir >0.5 mIU/mL
(red bar), and patients receiving FSH þ low-dose hCG with LH
nadir%0.5 mIU/mL (green bar). The addition of low-dose hCG in
patients with LH levels%0.5 mIU/mL resulted in outcomes similar
to those of patients with normal LH levels.
Propst. Low LH levels in IVF. Fertil Steril 2011.
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hMG or recombinant LH to ovarian stimulation reduces the number
of developing follicles and oocytes retrieved (28, 29, 34, 56, 57).
However this reduction in follicle number does not seem to
decrease the embryo yield or quality. In fact, a meta-analysis evalu-
ating recombinant LH supplementation found LH activity to be as-
sociated with a higher number of mature oocytes retrieved (62). This
is consistent with the experiments from Filicori’s group showing that
LH activity decreases the development of small oocytes but does not
decrease the pool of larger follicles. The LH/hCG activity increases
the activity of the enzymes involved in steroid production, leading to
increased substrate for conversion to estradiol. Several randomized
controlled trials have also confirmed this positive association with
hMG, recombinant LH, and hCG and increased peak estradiol levels
(12, 13, 15, 26, 28, 29, 34–41, 63). Our study is consistent with these
data in demonstrating that the addition of LH activity decreases the
overall oocyte yield and increases the peak estradiol levels.
Although our data show a significant improvement in live-birth
rates in patients with suppressed LH levels by the addition of low-
dose hCG, the overall live-birth rate was similar between both treat-
ment groups when all patients were included (48% vs. 50%, P¼.59).
This 2% difference in the live-birth rate is similar to that seen in two
meta-analyses evaluating the benefit of LH/hCG activity in the form
of hMG (64, 65). Both meta-analyses show a 3% to 4% increase in
live-birth rate in the hMG-treated groups; however, over 2,000 pa-
tients were required to find statistical significance (64, 65). Power
analysis of our own data suggests that approximately 5,000
patients would have to be randomized to show a statistically
significant improvement in the live-birth rate if all patients were in-
cluded.Wewere able to demonstrate a statistically significant differ-
ence in implantation and live-birth rate by analyzing just patients
with profound LH suppression.
Potential weaknesses of this study include its retrospective design
and relatively small sample size. Because the study compares pa-
tients before and after a protocol change in 2004 (the addition of
low-dose hCG to the stimulation protocol), potential bias exists if
improvement in other assisted reproduction techniques (ART)
were introduced during this time. We are not aware of any other ma-
jor changes in our ART protocol during this study period that may
have significantly introduced such bias. It should also be noted
that there are studies that do not support the concept that low LH
levels in GnRH antagonist cycles are associated with poor IVF out-
comes (2, 66, 67). For example, using the same threshold of%0.5
mIU/mL, Merviel et al. (67) did not find any significant detrimental
effect of low LH levels. Possible explanations for these differing
findings include OCP pretreatment, daily versus single dose
GnRH antagonist administration (4), variability in the sensitivities
of commercially available LH assays, and the fact that biochemical
assays of LH do not always accurately reflect LH bioactivity (68). It
is also possible that the time of day when the GnRH antagonist is
administered and when LH is measured could affect outcomes.
When LH levels were measured in a single patient every 15 minutes
for 24 hours, it was noted that in a single day the LH levels varied
from 1.8 mIU/mL just before antagonist treatment to 0.5 mIU/mL
6 hours later (5).When the discriminating thresholds for considering
adequate LH levels are so low, it is possible that the timing of med-
ication administration and serum hormone evaluation could influ-
ence results. It should also be noted that our cohort of patients
was pretreated with OCPs. It is possible that the benefit of low-
dose hCG in GnRH antagonist cycles is limited to patients pretreated
with OCPs. Caution should be taken in extrapolating our data to non-
OCP treatment cycles and further research to clarify this issuewould
be beneficial.
Our data show that profound suppression of LH levels after
GnRH antagonist administration is associated with reduced implan-
tation and live-birth rates. The addition of low-dose hCG to the IVF
stimulation protocol improves implantation and live-birth rates in
patients with low LH levels. This is consistent with a recent
meta-analysis that suggests a trend toward an increase in clinical
pregnancy rates in low-dose hCG protocols during GnRH-
antagonist cycles (69). However, there remains a lack of well-
designed, randomized, controlled trials evaluating this protocol,
and additional research is warranted.
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